Lesion Localization in Patients With a Previous Negative Transrectal Ultrasound Biopsy and Persistently Elevated Prostate Specific Antigen Level Using Diffusion-Weighted Imaging at Three Tesla Before Rebiopsy

Objective:To assess the use of diffusion-weighted imaging (DWI) at 3 Tesla (T) for lesion localization in patients with a high risk of prostate cancer before a rebiopsy. Materials and Methods:A total of 43 patients (age range, 40–80 years; mean age, 62.6 years) who had previously undergone a transrectal ultrasound (TRUS)-guided biopsy that was negative and continued to have a persistent elevated prostate specific antigen level underwent DWI with b = 0 s/mm2 and b = 1000 s/mm2 before a rebiopsy. We located the area of the lowest apparent diffusion coefficient values and performed a target biopsy of that area, followed by a systematic biopsy under TRUS guidance. We evaluated the cancer detection rate, tumor location, and lesion visibility on T2-weighted imaging (T2WI) in patients with biopsy-proven cancers. Results:Prostate cancer was detected in 17 (39.5%) patients, and was more predominant in the transitional zone (76.4%, 13/17) than in the peripheral zone (23.6%, 4/17) (P < 0.05). Of the 17 cancers detected on DWI, 6 lesions were seen on T2WI. Conclusion:DWI in addition to T2WI at 3 T has the potential to provide important information on lesion localization in patients that had both previous negative TRUS biopsy and persistently elevated prostate specific antigen levels before a repeated biopsy.

[1]  Peter Guion,et al.  Initial clinical experience with real‐time transrectal ultrasonography‐magnetic resonance imaging fusion‐guided prostate biopsy , 2008, BJU international.

[2]  Byung Kwan Park,et al.  Value of Diffusion-Weighted Imaging for the Prediction of Prostate Cancer Location at 3T Using a Phased-Array Coil: Preliminary Results , 2007, Investigative radiology.

[3]  Gabor Fichtinger,et al.  Patient selection determines the prostate cancer yield of dynamic contrast‐enhanced magnetic resonance imaging‐guided transrectal biopsies in a closed 3‐Tesla scanner , 2007, BJU international.

[4]  Masoom A Haider,et al.  Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. , 2007, AJR. American journal of roentgenology.

[5]  Guglielmo Manenti,et al.  Diffusion Tensor Magnetic Resonance Imaging of Prostate Cancer , 2007, Investigative radiology.

[6]  B. K. Park,et al.  Diffusion-Weighted Imaging of the Prostate at 3 T for Differentiation of Malignant and Benign Tissue in Transition and Peripheral Zones: Preliminary Results , 2007, Journal of computer assisted tomography.

[7]  Wha-Young Kim,et al.  Sonographic Findings in a Model of Ischemia-Induced Necrotizing Enterocolitis With Pathological Correlations , 2007, Investigative radiology.

[8]  Ashutosh Kumar Singh,et al.  Magnetic resonance imaging‐directed transrectal ultrasonography‐guided biopsies in patients at risk of prostate cancer , 2007, BJU international.

[9]  A. Hemal,et al.  Transrectal ultrasound‐guided biopsy of prostate voxels identified as suspicious of malignancy on three‐dimensional 1H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4–10 ng/ml , 2007, NMR in biomedicine.

[10]  H. Shinmoto,et al.  Prostate cancer screening: The clinical value of diffusion‐weighted imaging and dynamic MR imaging in combination with T2‐weighted imaging , 2007, Journal of magnetic resonance imaging : JMRI.

[11]  Heinz-Peter Schlemmer,et al.  MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. , 2006, European urology.

[12]  L. Turnbull,et al.  Diffusion‐weighted imaging of normal and malignant prostate tissue at 3.0T , 2006, Journal of magnetic resonance imaging : JMRI.

[13]  J. Kurhanewicz,et al.  Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. , 2005, Radiology.

[14]  M. Zerbib,et al.  Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study. , 2005, European urology.

[15]  Takeo Ishigaki,et al.  Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate , 2005, Journal of magnetic resonance imaging : JMRI.

[16]  Fritz Schick,et al.  Whole-body MRI at high field: technical limits and clinical potential , 2005, European Radiology.

[17]  K. Hosseinzadeh,et al.  Endorectal diffusion‐weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue , 2004, Journal of magnetic resonance imaging : JMRI.

[18]  Jacob Sosna,et al.  MR imaging of the prostate at 3 Tesla: comparison of an external phased-array coil to imaging with an endorectal coil at 1.5 Tesla. , 2004, Academic radiology.

[19]  L. Dougherty,et al.  High field body MR imaging: preliminary experiences. , 2004, Clinical imaging.

[20]  J. Hugosson,et al.  The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. , 2004, The Journal of urology.

[21]  M. Terris,et al.  Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. , 1989, The Journal of urology.

[22]  P. Grenier,et al.  MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. , 1986, Radiology.